{"id":"mk-1293","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL5775839","moleculeType":null,"molecularWeight":"495.58"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Glucagon receptor antagonists work by blocking the action of glucagon, a hormone that raises blood glucose levels. By inhibiting glucagon, MK-1293 aims to lower blood glucose levels in patients with type 2 diabetes.","oneSentence":"MK-1293 is a glucagon receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:34.149Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02059187","phase":"PHASE3","title":"The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-11","conditions":"Type 2 Diabetes Mellitus","enrollment":531},{"nctId":"NCT02059174","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-10","conditions":"Type 1 Diabetes Mellitus","enrollment":76},{"nctId":"NCT02059161","phase":"PHASE3","title":"A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-17","conditions":"Type 1 Diabetes Mellitus","enrollment":508}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK-1293","genericName":"MK-1293","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MK-1293 is a glucagon receptor antagonist. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}